Literature DB >> 22508783

Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer.

Jung Wook Huh1, Jae Hyuk Lee, Hyeong Rok Kim.   

Abstract

OBJECTIVE: To evaluate the prognostic significance of tumor-infiltrating lymphocytes (TILs) in patients with colorectal cancer.
DESIGN: A retrospective review of prospectively collected data.
SETTING: Tertiary care hospital. PATIENTS: A total of 546 patients who underwent curative surgery for primary nonmetastatic colorectal cancers from May 1, 2004, through December 31, 2007. MAIN OUTCOME MEASURES: The prognostic value of macroscopic ulceration, tumor border configuration, and TILs at the invasive margin was assessed.
RESULTS: The low TIL group was significantly correlated with a poorly differentiated status and perineural invasion. During the median 54-month follow-up period, the low TIL group had significantly lower 5-year overall survival and disease-free survival rates than the high TIL group of patients with stage III colorectal cancer (P = .005 and P = .03, respectively); however, for patients with stage I and II cancers, the survival rates did not differ between the 2 groups. The 5-year overall survival and 5-year disease-free survival rates were significantly different between the high and low TIL groups of patients with rectal cancer (P = .003 and P = .01, respectively). The multivariate analysis confirmed that the TIL grade was significantly and independently associated with a worse prognosis for overall survival but not for disease-free survival.
CONCLUSIONS: An inflammatory cell reaction at the tumor invasive border is considered a useful predictor of survival after colorectal cancer surgery, particularly for patients with stage III disease or rectal cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22508783     DOI: 10.1001/archsurg.2012.35

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  68 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer.

Authors:  Yunmei Liao; Juanjuan Ou; Jia Deng; Peiliang Geng; Rui Zeng; Yi Tian; Houjie Liang; Bing Ni; Zhihua Ruan
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

3.  TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients.

Authors:  Tatsuo Matsuda; Eisaku Miyauchi; Yu-Wen Hsu; Satoshi Nagayama; Kazuma Kiyotani; Makda Zewde; Jae-Hyun Park; Taigo Kato; Makiko Harada; Shimpei Matsui; Masashi Ueno; Kazumasa Fukuda; Nobuaki Suzuki; Shoichi Hazama; Hiroaki Nagano; Hiroya Takeuchi; Wickii T Vigneswaran; Yuko Kitagawa; Yusuke Nakamura
Journal:  Oncoimmunology       Date:  2019-03-22       Impact factor: 8.110

4.  Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.

Authors:  George Papaxoinis; Vassiliki Kotoula; Eleni Giannoulatou; Georgia-Angeliki Koliou; Vasilios Karavasilis; Sotirios Lakis; Andreas Koureas; Mattheos Bobos; Elpida Chalaralambous; Emily Daskalaki; Kyriakos Chatzopoulos; George Tsironis; Elisavet Pazarli; Sofia Chrisafi; Epaminontas Samantas; Ioannis G Kaklamanos; Ioannis Varthalitis; Athina Konstantara; Konstantinos N Syrigos; George Pentheroudakis; Dimitrios Pectasides; George Fountzilas
Journal:  Med Oncol       Date:  2018-05-31       Impact factor: 3.064

5.  Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy.

Authors:  Lin Wang; Zhi-Wei Zhai; Deng-Bo Ji; Zhong-Wu Li; Jin Gu
Journal:  Int J Colorectal Dis       Date:  2015-05-03       Impact factor: 2.571

Review 6.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Authors:  Geoffrey T Gibney; Louis M Weiner; Michael B Atkins
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

Review 7.  Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.

Authors:  Giovanni Tomasello; Pietro Tralongo; Provvidenza Damiani; Emanuele Sinagra; Benedetto Di Trapani; Marie Noelle Zeenny; Inaya Hajj Hussein; Abdo Jurjus; Angelo Leone
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

8.  Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tatsunari Fukuoka; Yasuhito Iseki; Shinji Matsutani; Shinichiro Kashiwagi; Hiroaki Tanaka; Kosei Hirakawa; Masaichi Ohira
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 9.  The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients.

Authors:  Andreas Nearchou; George Pentheroudakis
Journal:  Ann Transl Med       Date:  2016-07

10.  Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.

Authors:  Candice C Black; Mary Jo Turk; Konstantin Dragnev; James R Rigas
Journal:  Lung       Date:  2013-03-15       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.